Table 1.
Characteristics of the included studies
| Study | Study period | Country | Study design | Patients, No. | Age (y) | Male: female |
Primary tumor site | FU time (months), median |
Treatments | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tongue | Gingiva | Buccal | Mouth floor | Hard palate | Intraosseous | |||||||||
| Stanford-Moore et al. [28] | 2000–2020 | America | Retro | 38 | 67 ± 10.75 | 22:16 | 0 | 0 | 0 | 0 | 0 | 38 | 44.3 | chemoradiation therapy |
| Kashyap et al. [26] | NA | India | Retro | 14 | 38(29–59) | 12:2 | 2 | 0 | 12 | 0 | 0 | 0 | 14.6 | chemotherapy |
| Yoshida et al. [29] | 2004–2012 | Japan | Retro | 24 | 62 | 14.:10 | 36 | 0 | 7 | 2 | 0 | 14 | 60 | chemotherapy |
|
Kina et al. [27] |
2009–2017 | Japan | Retro | 106 | 61 ± 13 | 65:41 | 69 | 19 | 13 | 5 | 0 | 0 | 60 | chemotherapy |
| Yamakawa et al. ([30] | 2017–2019 | Japan | Retro | 143 | 65 (36–93) | 103:40 | 52 | 57 | 10 | 22 | 2 | 0 | 10.6 | Immunotherapy |
| Naruse et al. [31] | 2013–2017 | Japan | Retro | 31 | 64 (26–81) | 24.:7 | 10 | 14 | 1 | 4 | 0 | 2 | NA | chemoimmunotherapy |
|
Li et al. [32] |
2020–2022 | China | Retro | 104 | 57.5 (26–86) | 68:36 | 49 | 27 | 13 | 11 | 4 | 0 | 31 | chemoimmunotherapy |
| Shen et al. [33] | 2018–2021 | China | Retro | 30 | 58 (38–79) | 25:5 | NA | 13.5 | immunoradiotherapy | |||||
|
Liu et al. [34] |
2021–2022 | China | Prospective randomized trial | 68 | 50.7 (32–68) | 59:9 | 36 | 8 | 16 | 8 | 0 | 0 | 32 | chemoimmunotherapy |
|
Ju et al. [25] |
2020–2021 | China | Prospective study | 20 | 59.5 (36–73) | 11:9 | 11 | 3 | 5 | 1 | 0 | 0 | 18.5 | chemoimmunotherapy |